SCHEDULE: Invus Group Discloses 9.99% Stake in vTv Therapeutics

Investment entities linked to Raymond Debbane have reported a 9.99% beneficial ownership in vTv Therapeutics Inc., including common stock and warrants.

Summary

• Invus Public Equities, L.P., Avicenna Life Sci Master Fund LP, and related entities, along with Raymond Debbane, collectively reported beneficial ownership of 348,083 shares of vTv Therapeutics Inc. Class A Common Stock.
• This ownership represents 9.99% of the total issued and outstanding Class A Common Stock.
• The aggregate beneficial ownership includes 163,000 direct shares and 185,083 shares issuable upon the exercise of Pre-Funded Warrants and Common Warrants.
• The calculation of the percentage is based on 2,617,215 shares outstanding as of August 12, 2025, an additional 682,018 shares issued in a private placement on September 3, 2025, and the maximum 185,083 shares from warrants due to a beneficial ownership limitation.
• The reporting persons are subject to a Beneficial Ownership Limitation, preventing them from exercising warrants if it would result in owning more than 9.99% of the outstanding shares, though this limit can be changed with 61 days' notice.
• The securities were not acquired for the purpose of changing or influencing control of the issuer, except for activities related to a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a significant 9.99% stake by a sophisticated institutional investor group, including a life sciences fund, is generally a positive signal, indicating confidence in vTv Therapeutics. The inclusion of warrants suggests a long-term view and potential for future capital infusion upon exercise. The beneficial ownership limitation is a standard protective clause rather than a negative.

Positives

• A significant institutional investor, Raymond Debbane and associated Invus/Avicenna entities, has taken a substantial 9.99% stake in vTv Therapeutics, indicating confidence in the company.
• The investment includes both direct shares and warrants, suggesting a long-term interest and potential for increased ownership if the beneficial ownership limitation is adjusted.

Risks

• The Beneficial Ownership Limitation restricts the immediate full exercise of warrants if it would lead to ownership exceeding 9.99% of the total outstanding shares, potentially limiting the investor's flexibility or influence.
• The value of the warrants is dependent on the future performance of vTv Therapeutics' stock.

Future Outlook

The filing does not provide specific forward-looking statements or guidance from the company or the reporting persons, beyond the potential for warrant exercise subject to the beneficial ownership limitation.

Management Comments

• The filing includes a certification from Raymond Debbane, on behalf of all reporting persons, stating that the securities were not acquired for the purpose of changing or influencing control of the issuer, other than activities solely in connection with a nomination under Rule 14a-11.

Industry Context

This filing indicates a significant investment by a specialized life sciences fund and related entities in vTv Therapeutics, a company likely operating in the biotechnology or pharmaceutical sector. Such an investment by a sophisticated investor can signal confidence in the company's long-term prospects or its pipeline, aligning with broader trends of institutional capital flowing into promising biotech ventures.

Stakeholder Impact

• Shareholders: The entry of a significant institutional investor could be viewed positively, potentially stabilizing the stock and signaling external validation of the company's prospects. The private placement also diluted existing shareholders to some extent, but provided capital.
• Company Management: The presence of a large, sophisticated investor may lead to increased scrutiny or engagement regarding strategic decisions, although the filing states no intent to influence control beyond potential Rule 14a-11 nominations.
• Creditors: A capital raise (private placement) and potential future warrant exercises could improve the company's financial liquidity and reduce credit risk.

Next Steps

• The reporting persons may elect to change the 9.99% Beneficial Ownership Limitation upon 61 days' notice to the Issuer, potentially allowing for the exercise of more warrants in the future.
• vTv Therapeutics will continue its operations, potentially leveraging the capital raised from the private placement mentioned in the filing.

Key Dates

Recommendation

The filing indicates a significant vote of confidence from a sophisticated institutional investor group, which is a positive signal for vTv Therapeutics. The 9.99% stake, including warrants, suggests a long-term interest. However, a Schedule 13G is a disclosure of ownership, not a comprehensive financial report. It lacks detailed information on the company's operational performance, financial health, or strategic pipeline developments that would typically drive a 'buy' or 'sell' recommendation. Investors should 'hold' and await further fundamental analysis or company updates to make a more informed decision, while acknowledging the positive sentiment from this institutional backing.

Keywords

vTv Therapeutics, Invus Public Equities, Avicenna Life Sci, Raymond Debbane, Schedule 13G, beneficial ownership, common stock, warrants, private placement, institutional investment, biotechnology, pharmaceutical